Hang around pharmaceutical drug manufacturers long enough and the conversation
will undoubtedly turn to the global dilemma of safeguarding the public from the
proliferation of counterfeit drugs, and the Drug Quality and Security Act (DQSA). Now
a law, the DQSA includes a phased timeline, extending to 2023, that requires U.S.
prescription drug manufacturers to comply with a unified federal mandate regarding
transaction history and serialization. While the law eliminates the “wait-and-see”
attitude some manufacturers had taken, applying a synergistic approach to the forced
system and procedural updates can garner overwhelming benefits.
See entire paper here http://proddownloads.vertmarkets.com.s3.amazonaws.com/download/7e279107/7e279107-2ce9-4fd9-afe9-6c78a2e2e952/original/m_w_systech_wp_serialization_lsc20140422_rev0_email_rev.pdf